AMN107: Tightening the grip of imatinib
Authors:
- Denise K. WaltersDWDenise K. Walters
- Michael W.N. DeiningerMDMichael W.N. Deininger
- Brian J. DrukerBDBrian J. Druker
- 1 February 2005
- journal article
- review article
- Published by Elsevier in Cancer Cell
- Vol. 7 (2) , 117-119
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistanceProceedings of the National Academy of Sciences, 2005
- SRCircumventing imatinib resistanceCancer Cell, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- ADAMTS-13, VWF, inflammation, and thrombosisBlood, 2004
- Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistanceLeukemia, 2004
- Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia PatientsJournal of Clinical Oncology, 2004
- Faculty Opinions recommendation of Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).2002
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996